Table 3.
Treatment-emergent and drug-related adverse events
| Adverse event |
Participants, n (%) |
|||
| Grade I | Grade II | Grade III | Grade IV | |
| Hematological | ||||
| Decreased platelet count | 14 (21.2) | 8 (12.1) | 3 (4.5) | 0 (0) |
| Decreased neutrophil count | 15 (22.7) | 11 (16.7) | 2 (3.0) | 0 (0) |
| Non-hematological | ||||
| Elevated alanine | 30 (45.5) | 8 (12.1) | 4 (6.1) | 4 (6.1) |
| Elevated serum bilirubin | 20 (30.3) | 26 (39.4) | 5 (7.6) | 0 (0) |
| Nausea and vomiting | 32 (48.5) | 8 (12.1) | 0 (0) | 0 (0) |
| Pain | 29 (43.9) | 11 (16.7) | 0 (0) | 0 (0) |
| Fever | 4 (6.1) | 2 (3.0) | 0 (0) | 0 (0) |
| Diarrhea | 10 (15.2) | 6 (9.1) | 0 (0) | 0 (0) |
| Hand-foot skin reaction | 7 (10.6) | 16 (24.2) | 4 (6.1) | 0 (0) |
| Neurotoxicity | 18 (27.3) | 7 (10.6) | 0 (0) | 0 (0) |
Data are the number of patients, with percentages in parentheses; all participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma.